News | May 27, 2025
Aurobindo Pharma Q4 PAT falls marginally to Rs. 903 Cr
During the quarter, US formulations revenue increased by 13.5 per cent YoY to Rs. 4,072 crore
During the quarter, US formulations revenue increased by 13.5 per cent YoY to Rs. 4,072 crore
Net profit for the?quarter came in at Rs. 2,889.1 crore, up 4.8 per cent from the year earlier, adjusted for exceptional items
Akums invested Rs. 272 crore in capital expenditure during FY25
The company recorded its quarterly consolidated revenue from operations at Rs. 61.22 crore in Q4 FY25
R&D spend for Q4 was Rs. 50.3 crore, 4.9 per cent of Q4?revenue
The revenue witnessed a growth of 7.80 per cent on a year-on-year basis at Rs. 2,959 crore
Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore
For the full year FY25, net profit soared 12x to Rs 345 crore
The company has posted net profit of Rs. 40.88 crores for the Financial Year ended March 31, 2025
The company has posted net profit of Rs. 1,986.43 crores for the Financial Year ended March 31, 2025
Subscribe To Our Newsletter & Stay Updated
